ONENESS BIOTECH CO., LTD.
- Country
- 🇹🇼Taiwan
- Ownership
- Public
- Established
- 2008-06-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.onenessbio.com.tw
Clinical Trials
18
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers
- Conditions
- Diabetic Foot Ulcer
- Interventions
- Drug: Xianglei Tangzu GaoOther: Vehicle Cream
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Oneness Biotech Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06531512
- Locations
- 🇨🇳
Shenyang Seventh People's Hospital (Shenyang Hospital of Integrated Traditional Chinese and Western Medicine), Shenyang, Liaoning, China
🇨🇳The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
🇨🇳The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Oneness Biotech Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06397911
- Locations
- 🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇺🇸California Allergy and Asthma Medical Group, Los Angeles, California, United States
🇺🇸University of California, Davis Health, Department of Dermatology, Sacramento, California, United States
A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Oneness Biotech Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT05952986
- Locations
- 🇺🇸
Phase I center, Anaheim, California, United States
A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients
- Conditions
- Mild to Moderate COVID-19
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Oneness Biotech Co., Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT05941793
- Locations
- 🇺🇸
Velocity Clinical Research, Salt Lake City, Utah, United States
🇨🇳Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare, New Taipei City, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants
- Conditions
- Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
- Interventions
- Other: Placebo
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Oneness Biotech Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT05677893
- Locations
- 🇺🇸
Phase I Unit, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- 4
- Next